title: Etanercept-induced encephalopathy in a 7-year-old child.
abstract: Adverse events were reported in various patients treated with etanercept, including infections (sepsis and tuberculosis), malignancies (e.g., lymphoma), demyelinating disorders, and autoimmune diseases. Only two adult patients with etanercept-related encephalopathy were previously reported. We describe a 7-year-old patient who developed encephalopathy immediately after his third dose of etanercept. To the best of our knowledge, ours is the first report of a pediatric patient with a diagnosis of systemic arthritis and who developed etanercept-related encephalopathy.
authors: Department of Pediatric Neurology, Istanbul Medical Faculty, Istanbul University, Fatih, Istanbul, Turkey. ekicibaris@yahoo.com
authors: Barış
authors: B
authors: Ekici
authors: Kubilay
authors: K
authors: Aydın
authors: Serdar
authors: S
authors: Cantez
authors: Yakup
authors: Y
authors: Ergül
authors: Burak
authors: B
authors: Tatlı
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001921:Brain / Q000473:pathology*; D002648:Child; D004660:Encephalitis / Q000139:chemically induced* / Q000473:pathology; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept